Description du projet
Une plateforme de cancer sur puce pour la découverte de médicaments
Les cultures cellulaires tridimensionnelles font leur apparition en tant que modèles prometteurs pour la découverte de médicaments contre le cancer, la toxicologie ainsi que les études précliniques et de médecine personnalisée. Outre leur nature biomimétique et la reproductibilité des résultats, elles permettent également de réduire l’expérimentation animale. Le projet MImETIC INDiRECT, financé par l’UE, a mis au point un système de culture fondé sur la microfluidique composé d’une chambre pour puce recouverte d’une matrice extracellulaire ainsi que des capteurs d’oxygène et de température. Plus important encore, ce système utilise un milieu de culture contenant un facteur de croissance optimisé et est compatible avec les équipements d’imagerie. Les chercheurs emploieront des lignées cellulaires pour reconstruire des modèles de cancer 3D in vitro et promouvoir ces plateformes polyvalentes de cellules sur puce en vue de leur commercialisation.
Objectif
MImETIC INDiRECT aims to develop a standardised, accessible, versatile organ-on-chip toolkit for cancer biology and drug discovery research, compatible with microscopy-based (live imaging and confocal) techniques. The project is expected to facilitate academia and industry adoption of microfluidic 3D cell culture systems for comparable and reproducible results in a complex biomimetic animal free model for cancer drug discovery, toxicology, advanced (pre)clinical as well as personalized medicine. The toolkit components will consist of an integrated temperature controller dual-chamber chip, the Cherry Biotech CubiX system and growth factor optimized collagenous solutions for each chip chamber. The dual chamber chip, with cellular migration lanes, will have two tailored collagen-based formulations, designed per chamber. The CubiX platform is a compact flow and temperature controller, allowing optional sensor (e.g. O2) integration, compatible with single chips or 24-well plates. The cancer(s) sub-types to be used toolkit standardization will be dictated by market needs, where commercial cell lines (cancerous and non-cancerous) will be used to create the microvascularized complex tissue model. Potential project risks have been identified with appropriate mitigation strategies, where the project promotes adoption of standardized, cost-effective and versatile cancer organ-on-chip platforms in the market, rather than disruptive academic findings. Access of the aforementioned system to a worldwide growth market will fully exploit the project results, disseminated by direct and indirect marketing and scientific approaches. Project implementation will be an academic-industry collaborative and multidisciplinary manner providing the acquisition of diverse and unconventional complementary skills, leading to an understanding of both sectors requirements. We envision the above-mentioned to facilitate future academic and industry collaborations.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
Programme(s)
Régime de financement
MSCA-IF-EF-SE - Society and Enterprise panelCoordinateur
93100 Montreuil
France
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.